Advanced Cell Technology Comments on Recent Trading
Last update: 3/9/2011 12:15:01 PM
Phase I/II Trials Proceeding as Scheduled; Company Knows of No Reason for Decline in Stock Price
MARLBOROUGH, Mass., Mar 09, 2011 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ACTC), a leader in the field of regenerative medicine, commented today on recent trading activity in its stock. The Company knows of no business, clinical or financial reason for the stock's recent significant decline. The two Phase I/II clinical trials that ACT received FDA clearance on for its RPE program, including a Phase 1/2 trial in patients with dry age-related macular degeneration, are proceeding as scheduled.
ACT plans to update investors on its clinical trial progress when it holds a conference call for the investment community later this month in conjunction with the filing of its Form 10-K with the Securities and Exchange Commission.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit .
